FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	JVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LINK WILLIAM J PHD (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS] 3. Date of Earliest Transaction (Month/Day/Year)										Relationship heck all appli X Director Officer below)	cable) or (give title	g Pers	10% Ow Other (s below)	vner	
C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 (Street)				4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
IRVINE (City)	CA (Si	tate)	92618 (Zip)												Form Perso	filed by Mor		n One Repoi	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				. Transac	Execution Date,			3. Tra	3. Transaction Disposed Code (Instr. 5)		curiti	ies Acquire Of (D) (Ins	ed (A) or tr. 3, 4 ar	5. Amou Securiti Benefici Owned	nt of es ally following d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Т	able II - Do							l, Dis		of,	or Bendale secu	eficiall	y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	Transactio Code (Inst				6. Date Exercisa Expiration Date (Month/Day/Yea		e		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode V		(A)	(D)	Date Exercis	sable	Expiratio Date		Title	Amount or Number of Shares					
Stock Option (right to buy)	\$12.89	06/16/2022			A		7,000		(1))	06/15/203	32	Common Stock	7,000	\$0	7,000		D	
Restricted Stock Units	(2)	06/16/2022			A		2,000		(3))	(3)		Common Stock	2,000	\$0	2,000		D	

- 1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
- 2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- 3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

/s/ Leonard M. Greenstein

07/01/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.